RudaCure, a company specializing in developing treatments for eye diseases and 慢性疼痛, has been selected as a '宝贝独角兽' representing 韩国 in the bio sector, recognized for the innovativeness and growth potential of its technology. With this selection, RudaCure has achieved a double crown as a nationally representative promising 初创企业 following its 'BIG3' program selection in 2020.
RudaCure Inc. (CEO Yongho Kim) announced that it has been finally selected for the '2024 Global Unicorn Project' supported by the 中小企业部, enabling the company to receive full-scale growth support as a '宝贝独角兽' company for one year.
The 'Global Unicorn Project' is a national representative 初创企业 support policy to revitalize 韩国's 初创企业 ecosystem and nurture globally competitive 独角兽企业. Selected companies receive specialized support for 全球市场 entry, strategic 投资引进, and sustainable growth capabilities.
RudaCure was recognized for the innovative potential of its proprietary TRPV1 (瞫时受体电位香草酸亚型1) 离子通道 modulation-based 药物开发 technology, along with its achievements in attracting Series A/B investments totaling over KRW 16 billion and 技术转让 contracts exceeding KRW 70 billion.
CEO Yongho Kim stated, "Being selected for the Global Unicorn Project is meaningful recognition of RudaCure's growth potential and innovative technology. We will leverage this opportunity to accelerate our IPO preparations and strengthen our 全球市场 position."